Labcorp published workflow upgrades that boost nucleic acid yields and sequencing success from low‑input FFPE biopsy material, addressing a frequent bottleneck in oncology trials. The laboratory implemented automated dual-extraction protocols, enhanced QC metrics, and integrated broad genomic platforms to maximize variant detection from limited samples. Labcorp reported reductions in 'quantity not sufficient' (QNS) rates and improved downstream NGS performance, enabling more reliable comprehensive genomic profiling for patient selection and biomarker discovery. The improvements matter to sponsors running trials where biopsy amount and quality constrain enrollment and molecular endpoints.